News

Paracentral acute middle maculopathy can develop after excessive intake of caffeine and alcohol according to Obadah Moushmoush, MD.

Omnigen® may be an alternative treatment option for patients with a persistent corneal epithelial defect. The product provides a convenient and effective treatment that can be administered in an outpatient setting.

This two-in-one option, PreserVision AREDS 2 Formula eye vitamins plus CoQ10 combines the exact nutrient formula recommended by the National Eye Institute (NEI) to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.

The 12-month data demonstrated maintenance of controlled wet AMD subjects comparable to aflibercept injections every eight weeks with a single administration of OTX-TKI.

Investigators have enrolled the 112 patients in the KALAHARI phase 2, part B clinical trial for diabetic macular edema (DME). This is above the originally planned total of 108 patients.

The company’s pipeline includes treatments for XLRP, AMD, and cone-rod dystrophy (CRD).

Senescent cells accumulate in areas of disease activity in DME and wet age-related macular degeneration and release mediators that drive the pathology. UBX1325 seems to prevent that disease activity.

Patients who are non-responders to anti-vascular endothelial growth factor (VEGF) therapy may benefit from intravitreal dexamethasone.

Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.

Prompt evaluation and adherence to guidelines for treatment recommendations for lattice retinal degeneration are essential to the preservation of vision and sight.

RAFARM and BioNanoSim have entered into an agreement to create a new Opthalmic company: BNS Opthalmics (BNSO).

OTX-TKI is the Ocular Therapeutix’s axitinib intravitreal implant that is being developed for the treatment of diabetic retinopathy, wet AMD and other retinal diseases.

Ocular Therapeutix is scheduled to present trial results as well as participate in a panel discussion and sponsor a presentation at the 2023 Clinical Trials at the Summit Annual Meeting.

PAVIA is a 12-month, randomized, controlled phase 2 clinical trial of EYP-1901 in patients with moderate to severe NPDR.

This funding will allow for the registration and launch of gilderuretinol, the first and only medicine in clinical development to address the underlying mechanism of Stargardt disease.

Intelligent Retinal Imaging Systems (IRIS) celebrates the company’s 1 millionth diabetic retinal exam.

Aviceda Therapeutics doses its first patient with AVD-104 in its Phase 2 SIGLEC Trial. This intravitreal asset is being tried for treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection being assessed for the treatment of neovascular age-related macular degeneration (wet AMD).

The European Society of Ophthalmology (SOE) 2023 Congress will convene from June 15 to 17 in Prague, Czech Republic.

SOE holds a special place in its heart for the up-and-coming young ophthalmologists and is providing them a number of opportunities to hone their skills and establish professional contacts at this meeting.

Prevent Blindness marks its 115th birthday on June 1 by declaring it Prevent Blindness Day.

Reaching target enrollment is an important step toward Nacuity's goal to realize the potential of NPI-001 for patients affected by retinitis pigmentosa.

This positive data supports Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.

Optos announced the first ultra-widefield color rgb (red/green/blue) image. This new image modality is captured simultaneous to the optomap color rg image.

World No Tobacco Day helps to bring focus onto risk factors and symptoms of early vision loss linked to smoking.

VABYSMO is the first treatment for wet AMD and DME in Canada that acts by targeting both VEGF-A and Ang-2, two key drivers of vascular instability that have been associated with vision-threatening retinal conditions.

Results of the study, published in the Journal of Clinical Investigation, showed evidence that an experimental drug called 32-134D may prevent or slow vision loss in people with diabetes.

Oxurion NV has reached its enrollment target of 108 patients in its KALAHARI Phase 2, Part B clinical trial for diabetic macular edema (DME) and will likely continue to include additional participants in the trial due to high interest.

Alimera Sciences, Inc. has completed enrollment for its NEW DAY clinical trial (NCT04469595). Participants are patients diagnosed with diabetic macular edema (DME).

Curative Biotechnology Inc. has completed and filed a patent cooperation treaty (PCT) application with the U.S. Receiving Office.